Yup, it is an inference of the opposite - they met the "pre-specified efficacy end-point" with limited data so to speak. Besides, I don't think they could have met the 36 months criteria for all of them. Hence, it was an 'interim' analysis.
They cannot reads out the trial until they have all the data points as agreed with FDA.
I agree that the interim futility analysis (is there any improvement?) is different from a test for efficacy (how much does it improve?).
Yup, it is an inference of the opposite - they met the...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.46 |
Change
0.065(4.66%) |
Mkt cap ! $1.667B | |||
| Open | High | Low | Value | Volume |
| $1.41 | $1.50 | $1.40 | $5.699M | 3.943M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 122380 | $1.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 11015 | 2 |
View Market Depth
| Last trade - 16.10pm 11/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |